207 related articles for article (PubMed ID: 20535427)
21. The changing definition of contrast-induced nephropathy and its clinical implications: insights from the Blue Cross Blue Shield of Michigan Cardiovascular Consortium (BMC2).
Slocum NK; Grossman PM; Moscucci M; Smith DE; Aronow HD; Dixon SR; Share D; Gurm HS
Am Heart J; 2012 May; 163(5):829-34. PubMed ID: 22607861
[TBL] [Abstract][Full Text] [Related]
22. Impact of gender on the incidence and outcome of contrast-induced nephropathy after percutaneous coronary intervention.
Iakovou I; Dangas G; Mehran R; Lansky AJ; Ashby DT; Fahy M; Mintz GS; Kent KM; Pichard AD; Satler LF; Stone GW; Leon MB
J Invasive Cardiol; 2003 Jan; 15(1):18-22. PubMed ID: 12499523
[TBL] [Abstract][Full Text] [Related]
23. High-sensitivity C-reactive protein predicts contrast-induced nephropathy after primary percutaneous coronary intervention.
Liu Y; Tan N; Zhou YL; Chen YY; Chen JY; Chen J; Luo JF
J Nephrol; 2012; 25(3):332-40. PubMed ID: 21928234
[TBL] [Abstract][Full Text] [Related]
24. Predictive factors of contrast-induced nephropathy in patients undergoing primary coronary angioplasty.
Ivanes F; Isorni MA; Halimi JM; Fauchier L; Saint Etienne C; Babuty D; Angoulvant D; Brunet-Bernard A
Arch Cardiovasc Dis; 2014; 107(8-9):424-32. PubMed ID: 25082735
[TBL] [Abstract][Full Text] [Related]
25. Impact of Chronic Statin Therapy on Postprocedural Contrast-Induced Nephropathy in Patients Undergoing Non-Emergent Percutaneous Coronary Intervention.
Chanin JM; Yang DC; Haider MA; Swaminathan RV; Kim LK; Charitakis K; Tanoue M; Minutello RM; Gade CL; Singh HS; Bergman G; Wong SC; Feldman DN
J Invasive Cardiol; 2015 Nov; 27(11):490-6. PubMed ID: 25999136
[TBL] [Abstract][Full Text] [Related]
26. Contrast-induced nephropathy in patients undergoing primary percutaneous coronary intervention without acute left ventricular ejection fraction impairment.
Pyxaras SA; Sinagra G; Mangiacapra F; Perkan A; Di Serafino L; Vitrella G; Rakar S; De Vroey F; Santangelo S; Salvi A; Toth G; Bartunek J; De Bruyne B; Wijns W; Barbato E
Am J Cardiol; 2013 Mar; 111(5):684-8. PubMed ID: 23261003
[TBL] [Abstract][Full Text] [Related]
27. Relationship between red cell distribution width and contrast-induced nephropathy in patients who underwent primary percutaneous coronary intervention.
Akkoyun DÇ; Akyüz A; Kurt Ö; Bilir B; Alpsoy Ş; Güler N
Turk Kardiyol Dern Ars; 2015 Oct; 43(7):613-20. PubMed ID: 26536986
[TBL] [Abstract][Full Text] [Related]
28. Predictors of contrast-induced nephropathy in chronic total occlusion percutaneous coronary intervention.
Lin YS; Fang HY; Hussein H; Fang CY; Chen YL; Hsueh SK; Cheng CI; Yang CH; Chen CJ; Hang CL; Yip HK; Wu CJ
EuroIntervention; 2014 Feb; 9(10):1173-80. PubMed ID: 24561734
[TBL] [Abstract][Full Text] [Related]
29. Diastolic dysfunction predicts the risk of contrast-induced nephropathy and outcome post-emergency percutaneous coronary intervention in AMI patients with preserved ejection fraction.
Han B; Li Y; Dong Z; Wan Q; Shen H; Li J; Wei M; Shen C
Heart Vessels; 2018 Oct; 33(10):1149-1158. PubMed ID: 29704102
[TBL] [Abstract][Full Text] [Related]
30. Pre-diabetes and the risk of contrast induced nephropathy in patients undergoing coronary angiography or percutaneous intervention.
Barbieri L; Verdoia M; Schaffer A; Cassetti E; Di Giovine G; Marino P; Suryapranata H; De Luca G
Diabetes Res Clin Pract; 2014 Dec; 106(3):458-64. PubMed ID: 25458324
[TBL] [Abstract][Full Text] [Related]
31. Short-term, high-dose Atorvastatin pretreatment to prevent contrast-induced nephropathy in patients with acute coronary syndromes undergoing percutaneous coronary intervention (from the ARMYDA-CIN [atorvastatin for reduction of myocardial damage during angioplasty--contrast-induced nephropathy] trial.
Patti G; Ricottini E; Nusca A; Colonna G; Pasceri V; D'Ambrosio A; Montinaro A; Di Sciascio G
Am J Cardiol; 2011 Jul; 108(1):1-7. PubMed ID: 21529740
[TBL] [Abstract][Full Text] [Related]
32. Combined impact of chronic kidney disease and contrast-induced nephropathy on long-term outcomes in patients with ST-segment elevation acute myocardial infarction who undergo primary percutaneous coronary intervention.
Nakahashi H; Kosuge M; Sakamaki K; Kiyokuni M; Ebina T; Hibi K; Tsukahara K; Iwahashi N; Kuji S; Oba MS; Umemura S; Kimura K
Heart Vessels; 2017 Jan; 32(1):22-29. PubMed ID: 27106917
[TBL] [Abstract][Full Text] [Related]
33. Red cell distribution width predicts contrast-induced nephropathy in patients undergoing percutaneous coronary intervention for acute coronary syndrome.
Kurtul A; Yarlioglues M; Murat SN; Demircelik MB; Acikgoz SK; Ergun G; Duran M; Cetin M; Ornek E
Angiology; 2015 May; 66(5):433-40. PubMed ID: 24834929
[TBL] [Abstract][Full Text] [Related]
34. Comparison of iodixanol and ioversol for the prevention of contrast-induced nephropathy in diabetic patients after coronary angiography or angioplasty.
Hernández F; Mora L; García-Tejada J; Velázquez M; Gómez-Blázquez I; Bastante T; Albarrán A; Andreu J; Tascón J
Rev Esp Cardiol; 2009 Dec; 62(12):1373-80. PubMed ID: 20038403
[TBL] [Abstract][Full Text] [Related]
35. Risk stratification according to the type of impaired renal function in patients with acute myocardial infarction treated with percutaneous coronary intervention.
Kowalczyk J; Lenarczyk R; Kowalski O; Swiatkowski A; Stabryła-Deska J; Kurek T; Honisz G; Kukulski T; Gasior M; Kalarus Z
Kardiol Pol; 2007 Jun; 65(6):635-43; discussion 644. PubMed ID: 17629825
[TBL] [Abstract][Full Text] [Related]
36. Relation of uric acid and contrast-induced nephropathy in patients undergoing primary percutaneous coronary intervention in the ED.
Saritemur M; Turkeli M; Kalkan K; Tanboga İH; Aksakal E
Am J Emerg Med; 2014 Feb; 32(2):119-23. PubMed ID: 24238488
[TBL] [Abstract][Full Text] [Related]
37. [The relationship between hyperuricemia and contrast-induced nephropathy in patients with chronic kidney disease undergoing percutaneous coronary intervention].
Liu YH; Tan N; Liu Y; Ye P; He YT; Ran P; Jiang L
Zhonghua Xin Xue Guan Bing Za Zhi; 2013 Sep; 41(9):740-3. PubMed ID: 24331800
[TBL] [Abstract][Full Text] [Related]
38. Association of central pulse pressure with contrast-induced nephropathy and clinical outcomes in patients undergoing coronary intervention.
Huang SS; Huang PH; Leu HB; Wu TC; Lin SJ; Chen JW
J Hypertens; 2013 Nov; 31(11):2187-94. PubMed ID: 23868087
[TBL] [Abstract][Full Text] [Related]
39. A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention: development and initial validation.
Mehran R; Aymong ED; Nikolsky E; Lasic Z; Iakovou I; Fahy M; Mintz GS; Lansky AJ; Moses JW; Stone GW; Leon MB; Dangas G
J Am Coll Cardiol; 2004 Oct; 44(7):1393-9. PubMed ID: 15464318
[TBL] [Abstract][Full Text] [Related]
40. N-Terminal Fragment of Pro B-type Natriuretic Peptide as a Marker of Contrast-Induced Nephropathy After Primary Percutaneous Coronary Intervention for ST-Segment Elevation Myocardial Infarction.
Goussot S; Mousson C; Guenancia C; Stamboul K; Brunel P; Brunet D; Touzery C; Cottin Y; Zeller M
Am J Cardiol; 2015 Sep; 116(6):865-71. PubMed ID: 26183794
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
